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1193-28 C-Reactive Protein and Other Markers of Inflammation 
in Diabetic Patients With Unstable Angina/Non-ST 
Elevation Myocardial Infarction 
Pedro L. Sanchez. Jose L. Modnigo, Francisco Martin, Pedro Pabon, Antonio Ardbas, 
Ignacio Santos, Candido Martin-Luengo, University Hospital Salamanca, Spain. 
Background: Coronary tissue from diabetic patients (dp) exhibits a larger content of 
inflammatory cells than non-dp, suggesting an increased vulnerability for plaque disrup- 
tion. We investigated the differences in inflammatory status between dp and non-dp and 
evaluated the prognostic influence of different inflammatory markers in dp with acute cor- 
onary syndrome (ACS). 
Methods: Serum C-reactive protein (CRP), fibrinogen, and leukocyte count (LC) were 
measured at admission in 89 dp and compared with 178 gender and age-matched non- 
dp admitted in our hospital with non-ST elevation myocardial infarction/ IIIB unstable 
angina, and managed initially with a conservative strategy. Median follow-up was 1-year. 
Results: Median CRP (mg/dl), fibrinogen (mg/dl), and LC were higher in dp than in non- 
d (0,6 vs 0,4, 329 vs 286, and 9,000 vs 7,800, respectively; p<0.01). CRP and fibrinogen 
were higher (0.8 vs 0.5 and 351vs 281; p<0.01) in those dp with an adverse event 
(death, reinfarction or revascularization) during follow-up with no difference in LC. Rela- 
tive risks, after adjustment for the presence of conventional risk factors, according to 
fibrinogen, LC, troponin I and CRP are shown in the graphic. 
Conclusions: Inflammation, reflected in baseline serum inflammatory markers, appears 
to be more evident in d than in non-dp with ACS. These markers constitute an indepen- 
dent predictor of cardiac adverse events, suggesting that inflammation may contribute to 
the enhanced cardiac complications of dp with ACS. 
1193-29 Elevated C-Reactive Protein in Diabetics With Acute 
Coronary Syndrome: Culprit or Innocent Bystander? 
Harish R. Chandra, Cindy L. Grines, Carol S. O'Neill, Nivedita Choudhary, Judith Boura, 
Kishore J. Harjai, H.Mehrdad Sadeghi, James A. Goldstein, William W. O'Neill, William 
Beaumont Hospital, Royal Oak, Michigan. 
Background: Inflammation and diabetes have individually been associated with worse 
outcomes in patients with acute coronary syndrome (ACS). We evaluated whether there 
was an interaction between the two. 
Method: In a prospective study of 366 consecutive patients admitted with ACS, we evalu- 
ated the association between high sensitivity C-reactive protein (CRP) and diabetes. Clini- 
cal data and laboratory data were obtained at the time of admission. At 1 year the 
incidence of cardiac death was assessed. 
Result: Diabetics constituted 31% (n=114) of the study sample and had a higher level of 
mean CRP compared to the non-diabetics (0.77 vs. 0.46 mg/dl, p=0.002). CRP levels were 
independently associated with presence of diabetes (OR=1.59, p=0.005), age (OR=1.01, 
p--O.03), female gender (OR=1.53, p=0.008) and absence of hyperlipidemia (OR=0.71, 
p--0.025). There were 31(8.5%) cardiac deaths at 1 year which were similady distributed 
between diabetics and non-diabetics (11.4% vs. 7.1%, p=0.22). There was an incremental 
increase in cardiac death in both groups with increasing tertiles of CRP (p=0.0OO8)(Figure). 
Only CRP, age and congestive heart failure, but not diabetes, were independent predictors 
of death at 1 year by multivariate analysis. 
Conclusion: This study is the first to show that diabetics have a higher level of systemic 
inflammation i the setting of ACS. It also suggests that the increased incidence of cardiac 
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11 93-30 C-Reactive Protein, Pratreatment With Statins, and 
Muitifocal Activation of Coronary Artery Disease in 
Patients With Primary Unstable Angina 
Michael N. Zaids, Stavros Manousakis, Olga Papadakie, Denis Vitatis, Maria Thoma, 
Evangelos Tsanis, Thomas Matsikas, George Papadopoutos, Kostas Katseros, 
Demetdos Beldekos, Christopher Olympios, Stefanos Foussas, Cardiology Department, 
Tzanio Hospital, Piraeus, Greece. 
Background: Unstable angina (UA) results mainly from thrombosis uperimposed on 
ruptured coronary plaques. The components of the disrupted plaques contribute to the 
delineation of the angiographically rough contour of the complex lesion (CL). Multifocal 
activation of the coronary disease during acute coronary syndromes has been described. 
Moreover, inflammation appears to play a main role in the process of plaque rupture dur- 
ing these syndromes, and statin drugs seems to lower the blood levels of C-reactive pro- 
tein (CRP). The aim of this prospective study was to investigate the association of 
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plasma CRP levels upon admission, with the number of angiographically apparent CL in 
patients with primary UA. 
The influence of pretreatment with a statin on either plasma CRP levels or multifocal acti- 
vation of the coronary tree was also evaluated. 
Methods: A total of 251 consecutive pts with Braunwald IIIB UA who underwent in-hospi- 
tal catheterization and without condition that is known to influence CRP were studied. 
Coronary plaques were classified into CL or non-CL according to Ambrose's criteria. 
Results: There were 155 (61.8%) pts without or with single (<=1) CL and 96 pts with 
multiple (>=2) CLs in culprit or not-culprit arteries. 
There were 158 hypercholesterolemic (HCL) pts and 50 (19.9%) of these 158 pts had 
received statin for a median period of 14 months before UA. There was no significant dif- 
ference in the prevalence of HCL between pts with or without multiple CLs (64/96 66.7% 
vs. 94/155 60.6; p=0.34). Pts with multiple CLs had higher CRP values (2.2 mg/dl vs. 0.9 
mg/dl in pts with <=ICL; p<0.001) and HCL pts in this group were infrequently pretreated 
with statins (4/64 6.3% vs. 46/94 48.9% in pts with <=1CL; p<0.001 ).
By multivariate analysis elevated CRP was positively associated (RR=13.2, 95%C1=6.5- 
26.8, p<0.001) but pretreatment with a statin (RR=0.1.95%C1=0.04-0.4, p=0.001) was 
negatively correlated with the presence of angiographically multiple CLs. 
Conclusions: High plasma levels of CRP may be associated with the number of CLs in 
pts with primary UA. Pretreatment with a statin may prevent either CRP elevation or mul- 
tifocal activation of the coronary artery disease by its anti-inflammatory effect. 
1193-43 Can C-Reactive Protein Predict High Risk Coronary 
Angiographic Findings in Patients With Non-ST 
Elevation Acute Coronary Syndromes? A Large 
Prospective Cohort Study 
L~i~; A, Guzman-Cuneo, Jose L. Navarro Estrada, Jose Gabay, Jose AIvarez, Cados 
Sztejfman, Carlos Rojas Matas, Alejandra Farras, Ricardo Sarmiento, Jorge Mrad, Oscar 
Bazzino, Ra01 A. De Miguel, on Behalf of PACS Investigators, Buenos Aires, Argentina. 
Background: Inflammatory markers have been associated with adverse clinical outcome 
in patients with acute coronary syndromes (ACS). In addition, angiographic plaque mor- 
phology has been related to worse prognosis, and a strong relationship was seen 
between myocardial injury markers, like troponin t, and the presence of complex coro- 
nary lesions (CCL). Even though inflammation has been postulated as an important fac- 
tor in the pathophysiology of ACS, the role of inflammatory markers in predicting 
angiogrephic findings has not been established. The aim of the present study was to 
determine if C-reactive protein (CRP), an inflammatory marker, may predict he presence 
of CCL. Methods: This prospective multicenter cohort study included 1,253 pts with non- 
ST elevation ACS. CRP, considered (+) if > 3 mg/L, was measured at a median of 9 hrs 
from symptoms onset and were kept blinded up to the end of the study. Coronary angiog- 
raphy was performed in 579 pts (46%), and reviewed by two angiographers unaware of 
the lab results and clinical course, CCL was defined as the presence of any of the follow- 
ing: Thrombus (+), TIMI flow <2 or ulcerated plaque (UP). Results: 
PCR (+) n:341 PCR (-) n:228 P value 
Thrombus (+) n:108 65 (19%) 40 (18%) 0.91 
TIMI < 2 n:140 82 (24%) 53 (23%) 0.91 
UP n:148 91 (27%) 57 (25%) 0.72 
CCL n:266 163 (48%) 97 (42%) 0.25 
Conclusions: In this large consecutive cohort of non-ST elevation ACS patients, C-Reac- 
tive Protein, an inflammatory marker, does not predict he presence of any of the different 
component of a complex "acute" coronary lesion. Even though CRP is a strong predictor 
of worse clinical outcome, this could not be explained by the presence of more complex 
coronary anatomy 
1193-44 Thrombogenic Risk Factors in Patients Who Suffered a 
Myocardial Infarction Under the Age of 36 Years 
Loukianos S. Rallidis, Chrusula I. Belesi, Helen S. Manioudaki, Velsa C. Fakitsa, Vassilis 
K. Chatziioakimidis, Nikolaos P. Laoutaris, Thomas Apostolou, Evangelos G. 
Papasteriadis, General Hospital of Nikea, Piraeus, Greece. 
Background: the contribution of hereditary thrombogenic disorders in the pathogenesis 
of myocardial infarction (Mi) in young patients (pts) is not well elucidated. We examined 
the prevalence of these factors in pts who suffered a MI <35 years, 
Methods: we recruited 40 consecutive pts -<35 years (mean age=32.4:t:2 years, range 
25-35 years, 34 men) who admitted to the Coronary Care Unit over the period 1998-2000 
with the diagnosis of acute MI. All these pts underwent coronary angiography. Two 
months after discharge blood was taken and tested for the presence of factor V G1691A 
mutation using polymerase chain reaction. In addition, the concentration ofprotein C and 
antithrombin Ill (ATlll) was measured using functional chromogenic method and the con- 
centration of protein S using coagulometric method. The control group consisted of 309 
healthy blood donors matched for age and gender with the MI pts. 
Results: 10 (25%) of pts had normal coronary arteries, 18 (45%) one vessel disease and 
12 (30%) multivessel disease. The table shows the results and the comparison between 
the young MI pts (n=40) and the control group (n=309) [chi-square test was applied with 
continuity correction]. 
Young MI pts Control group p 
Eterozygotes for factor V mutation 4/40 (10%) 18/309 (5.8%) NS 
Deficiency of protein C 2/40 (5%) 1/309 (0.3%) 0.03 
Deficiency of protein S 1/40 (2.5%) 3/309 (0.97%) NS 
Deficiency of ATIII 1/40 (2.5%) 2/309 (0.65) NS 
Double deficiency of proteins C+S 2/40 (5%) 1/309 (0.3%) 0.03 
Total disorders 9/40 (22.5%) 25/309 (8.1%) 0.002 
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There was no difference in the prevalence of thrombogenic disorders among the survi- 
vors of MI according to the presence of normal or diseased coronary arteries. 
Conclusions: there is a relatively high prevalence of hereditary thrombogenic disorders 
in pts who suffered a MI _<35 years, and this may contribute to the pathogenesis of MI in 
young pts. 
1193-45 Is Age Related to Platelet Activity in Patients Presenting 
With Acute Coronary Syndromes? 
Paul A. Gurbel, E. Magnus Ohman, Matthew T. Roe, Raymond D. Bahr, W. Brian Gibler, 
Victor L. Serebruany, for the EARLY Thai Investigators, Sinai Hosptial, Baltimore, 
Maryland, Duke University, Durham, North Carolina. 
BACKGROUND: Bleeding is a major risk of pharmacologic strategies to treat acute cor- 
onary syndromes (ACS) and is increased in the eldedy. This risk may be related to an 
age-dependent reduction in platalet activity.METHODS: Baseline platelet function and 
flow cytometry with menoclonal antibodies directed against multiple surface receptors 
were investigated in a substudy of the EARLY Trial (n=56) that treated patients present- 
ing to the Emergency Department with early or late (12-24 hours) eptifibatide.RESULTS: 
A significant negative correlation was observed between age and indicators of platelet 
activity. PAC-1 expression, a marker of Gp lib/Ilia activity, fell as age increased (r = - 
.5250) and platelet aggregation to 10H tool ADP was also lower in the elderly (r = -.5938, 
see figure). CONCLUSION: At presentation to the Emergency Department with acute 
coronary syndromes, older patients have less active platelets. The age-dependent 
increase in bleeding risk in the elderly may be related to reduced platelet activity as com- 
pared to younger patients. Monitodng of platelet function may lessen the bleeding risks in 
ACS treatment by appropriate adjustment of platelet inhibition. 
age w p4awlm a~lrellatlon 
C Ofrela~on: r= ..5938 
11o 
~ ~'~%L~'"  
7O . ~  




2030 ~ ~) 50 70 80 90 1oo ~% ¢onfid 
age (years) 
1193-46 Sustained Reduction in Coagulation Activity During 
Long-Term Dalteparin Treatment in Unstable Coronary 
Artery Disease 
Jonas Oldaren. Edk Diderbolm, Eva Lindmark, Lars Wallentin, Agneta Siagbahn, Medical 
Sciences, Cardiology and Clin Chemist~ Uppsala, Sweden. 
Background: Short-term treatment with low molecular mass heparin is known to reduce 
coagulation activity. We have investigated the influence on markers of coagulation activ- 
ity by long-term treatment with dalteparin, a low molecular mass heparin, in patients with 
unstable coronary artery disease (CAD). 
Methods: Coagulation activity was monitored in 562 out of the 2267 patients with unsta- 
ble CAD in the Scandinavian multicenter study FRISC II. All patients were treated with 
subcutaneous dalteparin 120 IU/kg twice daily for 5-7 days and then randomised to pla- 
cebo (n=287) or long-term treatment with daltaparin (n=275) for 3 months. Women 
weighing < 80 kg, and men weighing < 70 kg, received daltaparin 5,000 IU twice daily 
and above these weight limits the daltaparin dose was 7,500 IU twice daily during long- 
term treatment. Prothrombin fragment 1+2 (F1+2) and D-dimer were analysed during in- 
hospital daltepadn treatment, during long-term daltaparin/placabo treatment at 6 weeks 
and 3 months, and at 6 months follow-up. Data are medians with Mann Whitney test. 
Results: See table 
Conclusion: There was a sustained reduction of coagulation activity, as indicated by 
lower levels of F1+2 and D-dimer, dudng long-term treatment with dalteparin as com- 
pared to placebo. A significantly higher coagulation activity was seen at follow-up 3 
months after termination of long-term daltaparin treatment, whereas coagulation activity 
was unchan~led at follow-up in the placebo group. 
F1+2, nmol/L D-dimer. microg/L 
daltepadn, 120 IU/kg p dalteparin, 120 IU/kg p 
In-hospital 0.79 0.78 0.8 30 31 0.5 
daltaparin placebo daltaparin placebo 
6 weeks 0.87 1.15 <0.001 20 43 <0.001 
3 months 0.86 1.10 <0.001 21 42 <0:001 
Post-treatment Post-treatment 
6 months 1.05 1.11 0.2 36 38 0.1 
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1193-47 Enhaoed Cort iso l  Secretion Does Not Control Aspirin- 
Insensitive Thromboxane Biosynthesis in Patients With 
Acute Coronary Syndromes 
Giulia Renda, Maria G. Sciulli, Francesca Seta, Stefania Tecconelli, Marta L. Capone, 
Antonio Rebuzzi, Paola Patrianani. "G. D'Annunzio" University of Chieti School of 
Medicine, Chieti, Italy, Catholic University School of Medicine, Rome,/ta/y 
We have explored 1) the involvement of monocyte COX-2 induction in enhanced throm- 
boxane (TX) A2 biosynthesis occurring episodically in patients with acute coronary syn- 
dromes treated with low-dose aspidn, and 2) the influence of endogenous cortisol 
secretion in TXA2 biosynthesis in this setting. Whole blood TXB2 and udnary 11-dehy- 
dro-TXB2 and cortisol levels were evaluated by RIA. In patients with acute myocardial 
infarction (AMI; n=15), unstable angina (UA; n=10) and chronic stable angina (CSA; 
n=15), the treatment with low-dose aspirin (160 mg/d) caused a similar suppression of 
platalet COX-1 activity while the biosynthesis of TXA2. in vivo, as reflected by the excre- 
tion of 11-dehydro-TXS2 in overnight udne samples, was significantly higher in patients 
with AMI and UA vs. SA [206±161 (p<O.01) and 126±86 (p<O.05) vs. 69±34 pg/mg crea- 
tinine, respectively]. The production of TXB2 in heparinized whole blood incubated for 4 h 
with bectedal endotoxin (LPS, 1 ~g/ml) was significantly (p<0.05) higher in patients with 
AMI vs. CSA but not vs. UA (52±29, 26.8±17 and 30±21 pg/lO 3 monocytes) and was pro- 
foundly suppressed (77-87%) by the selective COX-2 inhibitor L-745,337 (26 p.M). 
Plasma levels of C-reactive protein (CRP), a marker of systemic inflammation, were 
higher in patients with AMI and UA vs. those with CSA [40±43 (p<0.01) and 15±14 
(p<0.05) vs. 3.9±2.6 rag/I]. The urinary excretion of cortisol was significantly (p<0.01) 
higher in patients with AMI vs. those with UA and CSA [176±130, 58±57 and 46±52 ng/ 
mg creatinine]. Urinary cortisol correlated with 11-dehydro-TXB2 (r=0.516, n=36, 
p<0.01), LPS-induced TXB2 (r=0.552, n=20, p<0.05) and plasma CRP (r=0.408, n=36, 
p<0.05). Differently from patients with SA, in AMI and UA, the circadian rhythm of urinary 
cortisol excretion did not occur. In conclusion, COX-2 expression in circulating mono- 
cytes may participate in episodes of aspirin-insensitive TXA2 biosynthesis in acute coro- 
nary syndromes. Activation of the hypothalamic-pituitary-edrenal axis occurs in patients 
with acute coronary syndromes but it seems insufficient o control the inflammatory reac- 
tion presumably triggering aspirin-insensitive TXA2 biosynthesis in this setting. 
1193-48 Increased Homocysteine Levels Predict a More 
Complicated Course Following Acute Myocardial 
In farct ion 
Shlomi Matetzky. Dov Freimark, Sela Ben-Ami, Ilya Novikov, Michael Eldar, Hanoch Hod, 
Heart Institute Sheba Medical Center, Tel Hashomer, Israel 
Background: Although hyperhomocysteinema is associated with hypercoagulability and 
piatelet aggregation, and interferes with fibrinolysis, data are scarce regarding the effect 
of hyperhomocystaine levels on clinical outcome in patients with acute myocardial infarc- 
tion (AMI). 
Methods: Homocystaine was determined on admission in 160 consecutive patients with 
AMI by HPLC methodology with fluorescent detection. 
Results: Mean homocysteine levels in the entire group were 14±11 micromole/L. 
Homocysteine levels were higher in male (p<0.01) and non-diabetic patients (p<0.Ol), 
but were not associated with other risk factors or age (r=0.07, p=0.42). Patients (n=22) 
with homocysteine 320 micromole/L (34±9) compared with those of lower levels (n=135, 
10±4), had a lower incidence of diabetes mellitus (9% vs 28%, p=0.06). There was no 
significance difference regarding the in-hospital course and indices of infarct size, includ- 
ing peak CPK (p=0.7) and LVEF (p=0.45) in both groups of patients. Among the 112 
catheterized patients, those with homocysteine 320 and <20 micromol/L had a similar dis- 
tribution of the infarct-related artery, number of diseased coronary artedes (p=0.87) and 
prevalence of multi-vessel coronary artery disease (p=0.9). However, during mean fol- 
low-up of 30 months, the patients with higher homocysteine levels had a higher incidence 
of re-hospitalization for recurrent coronary events (38% vs 17%, p<0.O4) and a higher 
mortality rate (18% vs 5%, p<0.05). 
Conclusion: Elevated levels of homocystaine in AMI patients are associated with a higher 
incidence of recurrent coronary events and mortality. 
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1194-38 Pred ic tors  of  Emergency Coronary Artery Bypass 
Grafting in Percutaneous Coronary Interventions 
Niranjan Seshadri, Naveen Acharva. Penny Houghtaling, Eugene Blackstone, Stephen 
G. Ellis, Patrick L. Whitlow, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background and Aim: Advances in interventional cardiology have resulted in a 
decreased need for emergency coronary artery bypass grafting (EMCABG) following 
percutaneous coronary interventions (PCI). We sought to determine the current preva- 
lence and predictors of EMCABG. 
Methods: A retrospective review of all PCIs performed for a 4-year period between 1/2/ 
1997 and 12/29/2000 at our institution. Multivadable logistic regression modeling was 
performed to determine predictors of EMCABG. 
Results: There were 8830 PCI procedures performed (mean age 64± 12 yrs, 2575 F, 
